Evidence map›Paper›PMID 24478102›Full record

ArticleInfection and immunity2014

Oral immunization with Escherichia coli expressing a lipidated form of LigA protects hamsters against challenge with Leptospira interrogans serovar Copenhageni.

Kristel Lourdault, Long-Chieh Wang, Ana Vieira, James Matsunaga, Rita Melo, Michael S Lewis, David A Haake, Maria Gomes-Solecki

Open access · bronzeAbstract read
In one paragraph

Article in Infection and immunity, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
3.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Deciphering the Role ofFrontiers in immunology · 2021
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Spirochetal Lipoproteins and Immune Evasion.Frontiers in immunology · 2017
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kristel LourdaultVA Greater Los Angeles Healthcare System, Los Angeles, California, USA.
Long-Chieh Wang
Ana Vieira
James Matsunaga
Rita Melo
Michael S Lewis
David A Haake
Maria Gomes-Solecki
VA Greater Los Angeles Healthcare System · USUniversity of Tennessee Health Science Center · US

Funding

Outer Membrane Proteins of Pathogenic Leptospira SpeciesR01AI034431 · NIAID · BRENTWOOD BIOMEDICAL RESEARCH INSTITUTE · PI GOMES-SOLECKI, MARIA, HAAKE, DAVID A · 2003 to 2015
$4.1M
Lab on a chip point of care assay for the rapid serodiagnosis of Lyme diseaseR44AI096551 · NIAID · IMMUNO TECHNOLOGIES, INC. · PI GOMES-SOLECKI, MARIA · 2014 to 2016
$3.0M
Lab on a chip point of care assay for the rapid serodiagnosis of Lyme diseaseR43AI096551 · NIAID · BIOPEPTIDES, INC. · PI GOMES-SOLECKI, MARIA · 2011 to 2012
$600k
The Leptospiral Outer Membrane Proteome & ImmunityI01BX002003 · VA · VA GREATER LOS ANGELES HEALTHCARE SYSTEM · PI MATSUNAGA, JAMES · 2014 to 2022
–
NCEZID CDC HHS U01 CK000107NIAID NIH HHS R01 AI034431NIAID NIH HHS R43 AI096551
6 · The paper itself

Abstract

Leptospirosis is a potentially fatal zoonosis transmitted by reservoir host animals that harbor leptospires in their renal tubules and shed the bacteria in their urine. Leptospira interrogans serovar Copenhageni transmitted from Rattus norvegicus to humans is the most prevalent cause of urban leptospirosis. We examined L. interrogans LigA, domains 7 to 13 (LigA7-13), as an oral vaccine delivered by Escherichia coli as a lipidated, membrane-associated protein. The efficacy of the vaccine was evaluated in a susceptible hamster model in terms of the humoral immune response and survival from leptospiral challenge. Four weeks of oral administration of live E. coli expressing LigA7-13 improved survival from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans serovar Copenhageni strain Fiocruz L1-130 in Golden Syrian hamsters. Immunization with E. coli expressing LigA7-13 resulted in a systemic antibody response, and a significant LigA7-13 IgG level after the first 2 weeks of immunization was completely predictive of survival 28 days after challenge. As in previous LigA vaccine studies, all immunized hamsters that survived infection had renal leptospiral colonization and histopathological changes. In summary, an oral LigA-based vaccine improved survival from leptospiral challenge by either the i.p. or i.d. route.

Indexed as

Administration, OralAnimalsAntibodies, BacterialBacterial VaccinesCricetinaeDisease Models, AnimalDNA LigasesDrug CarriersEscherichia coliFemaleImmunizationImmunoglobulin GLeptospira interrogansLeptospirosisMesocricetusSurvival AnalysisAntibodies, BacterialBacterial VaccinesDNA LigasesDrug CarriersImmunoglobulin G

Identifiers

PMID24478102
PMCPMC3911400
OpenAlexW2021917182

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.